General
Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Sonneveld P et al. Blood. 2016 Mar 21. pii: blood-2016-01-631200. [Epub ahead of print]. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. Wahaib K et al. Am J Health Syst Pharm. 2016 Apr 1;73(7):441-50. doi: 10.2146/ajhp150487. Haematological cancer: PomCyDex – a lower-cost option in refractory myeloma?…